Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Treasury Shares (2022 - 2025)

Historic Treasury Shares for Lyra Therapeutics (LYRA) over the last 4 years, with Q3 2025 value amounting to $58882.0.

  • Lyra Therapeutics' Treasury Shares fell 9321.22% to $58882.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $58882.0, marking a year-over-year decrease of 9321.22%. This contributed to the annual value of $42865.0 for FY2024, which is 5919.48% down from last year.
  • Latest data reveals that Lyra Therapeutics reported Treasury Shares of $58882.0 as of Q3 2025, which was down 9321.22% from $85804.0 recorded in Q2 2025.
  • In the past 5 years, Lyra Therapeutics' Treasury Shares registered a high of $4.7 million during Q1 2025, and its lowest value of $28212.0 during Q4 2022.
  • Moreover, its 4-year median value for Treasury Shares was $105048.0 (2023), whereas its average is $581525.7.
  • In the last 5 years, Lyra Therapeutics' Treasury Shares surged by 58807.67% in 2023 and then tumbled by 9321.22% in 2025.
  • Over the past 4 years, Lyra Therapeutics' Treasury Shares (Quarter) stood at $28212.0 in 2022, then soared by 272.35% to $105048.0 in 2023, then plummeted by 59.19% to $42865.0 in 2024, then skyrocketed by 37.37% to $58882.0 in 2025.
  • Its Treasury Shares stands at $58882.0 for Q3 2025, versus $85804.0 for Q2 2025 and $4.7 million for Q1 2025.